tirzepatide ulcerative colitis glp 1 for If you are living with Crohn's disease or and you have Patients with stable inflammatory bowel

I firmly believe I was insulin resistant especially as I get older

The risk-benefit discussion should include GI intolerance, dehydration/renal risk, gallbladder disease, pancreatitis warning symptoms, diabetic retinopathy monitoring in some patients, hypoglycemia risk when combined with insulin/sulfonylureas, and the thyroid C-cell tumor contraindication context

The Lancet Diabetes & Endocrinology, 9 (9), 563574

Over 72 weeks patients without diabetes lost 15%, 19%, and 21% of body weight on the 5, 10, and 15 mg weekly SQ injections, respectively

But having organised, accurate records of your journey means those conversations are better informed